A weekly check-in on Med BioGene Inc reveals steady performance amid limited news.
Med BioGene Inc (TSXV: MBI-H) has maintained a stable position in the market, with no significant price movements observed this week. The company, which focuses on genomic-based testing, remains under the radar given its small-cap status.
Advertisement
Med BioGene Inc
MBI-H.V
MBI-H.V
Med BioGene Inc
WealthAwesomeMarket cap
$172,578
52W high
$0.03
52W low
$0.01
1W change
+50.00%
Beta
1.48
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on MBI-H's historical volatility
30-Day Vol
278.0%
Annualized
90-Day Vol
236.4%
Annualized
Trend (90d)
-50.0%
Annualized drift
90d Mean
C$0.01
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$0.01 | C$0.01 – C$0.04 |
| 60 trading days | C$0.01 | C$0.00 – C$0.05 |
| 90 trading days | C$0.01 | C$0.00 – C$0.07 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Investor takeaway: Investors should consider the company's limited news flow and small market cap when evaluating potential risks and opportunities.
C$0.03 Closing Price with Steady Performance
Med BioGene Inc's stock has seen a 50% increase year-to-date, yet remains significantly lower than its historical highs.
Bull case
The recent 50% gain this year suggests potential for growth, especially if the company can tackle its regulatory challenges and enhance trading conditions.
Bear case
The absence of significant news and the company's small market cap could lead to increased volatility, particularly given its past performance decline over the last five years.
Price Action Overview
This week, Med BioGene Inc's stock closed at C$0.03, reflecting no change in price over the past day, week, and month. Year-to-date, the stock has appreciated by 50%. Despite this positive trend, trading volume has been relatively low, with only 2,000 shares exchanged compared to a 20-day average volume of 40,000 shares.
Advertisement
Technical Picture
The technical indicators for Med BioGene Inc show a 50-day moving average at C$0.03, which aligns with the current stock price, indicating a flat trend. The 200-day moving average stands at C$0.03, suggesting a potential upward momentum of 18.6%. The stock has a 52-week range of C$0.02 to C$0.05, with the current price at 33% of this range. The beta of 1.57 indicates a higher volatility compared to the market.
Recent Company News
Currently, there are no major news updates directly from Med BioGene Inc. However, recent headlines indicate that the trading of the stock was previously halted by the Canadian Investment Regulatory Organization due to regulatory compliance issues. The company has since taken steps to address these issues and is working towards a reinstatement of trading.
Market Sentiment
Recent analysis indicates a bearish sentiment towards Med BioGene Inc, with a 'Sell' consensus reported. This reflects a cautious outlook from analysts, with 12 bearish indicators, 3 neutral, and 5 bullish. Investors should remain informed about these sentiments as they navigate their investment decisions.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
